Study: Early treatment with fluvoxamine may prevent serious respiratory problems

20 November, 2020

Early treatment with the antidepressant fluvoxamine (Luvox) may help prevent respiratory deterioration in patients with mild symptomatic COVID-19, results of a small and preliminary randomized controlled trial published in JAMA suggest.

In the trial, none of the patients who took fluvoxamine within 7 days of first symptoms developed serious breathing difficulties or required hospitalization for respiratory deterioration.

The authors caution that the study was small and with short follow-up, and that the findings "need to be interpreted as hypothesis generating rather than as a demonstration of efficacy."

LATEST NEWS

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  • COVID-19 in Botswana

    Botswana // 03 December, 2020

    At least 10,000 cases and 34 deaths. Outbreak...

    COVID-19

  • COVID-19 in Eswatini

    Eswatini // 03 December, 2020

    Over 6,000 cases and 120 deaths. Increasing activity...

    COVID-19

  • COVID-19 in Eritrea

    Eritrea // 03 December, 2020

    Over 500 cases. Limited activity...

    COVID-19

  • COVID-19 in Equatorial Guinea

    Equatorial Guinea // 03 December, 2020

    Over 5,000 cases confirmed, and at least 85 deaths. Limited Activity...

    COVID-19

  • COVID-19 in DRC

    Congo DRC // 03 December, 2020

    More than 12,000 cases and over 300 deaths. Limited Activity...

    COVID-19

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Webinars

Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars